European Medicines Agency recommends approval of first higher-strength...
London, 23-10-2012 — /europawire.eu/ — The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a recommendation to give marketing authorisation to insulin...
View ArticleRoche’s Perjeta recommended for approval in EU as pre-surgery breast cancer...
The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the benefit in achieving pathological complete response (pCR) BASEL,...
View ArticleAstraZeneca announces positive CHMP opinion recommending the approval of new...
LONDON, 02-May-2016 — /EuropaWire/ — AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion,...
View ArticleEU Committee for Medicinal Products for Human Use (CHMP) recommends EU...
In the pivotal study, treatment with Gazyvaro plus bendamustine chemotherapy reduced the risk of disease worsening or death by 52 percent compared to bendamustine alone BASEL, 04-May-2016 —...
View ArticleEuropean Medicines Agency recommends approval of first higher-strength...
London, 23-10-2012 — /europawire.eu/ — The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a recommendation to give marketing authorisation to insulin...
View ArticleRoche’s Perjeta recommended for approval in EU as pre-surgery breast cancer...
The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the benefit in achieving pathological complete response (pCR) BASEL,...
View ArticleAstraZeneca announces positive CHMP opinion recommending the approval of new...
LONDON, 02-May-2016 — /EuropaWire/ — AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion,...
View ArticleEU Committee for Medicinal Products for Human Use (CHMP) recommends EU...
In the pivotal study, treatment with Gazyvaro plus bendamustine chemotherapy reduced the risk of disease worsening or death by 52 percent compared to bendamustine alone BASEL, 04-May-2016 —...
View ArticleSandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts...
Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on...
View ArticleEuropean Medicines Agency recommends approval of first higher-strength...
London, 23-10-2012 — /europawire.eu/ — The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a recommendation to give marketing authorisation to insulin...
View ArticleRoche’s Perjeta recommended for approval in EU as pre-surgery breast cancer...
The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the benefit in achieving pathological complete response (pCR) BASEL,...
View ArticleAstraZeneca announces positive CHMP opinion recommending the approval of new...
LONDON, 02-May-2016 — /EuropaWire/ — AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion,...
View ArticleEU Committee for Medicinal Products for Human Use (CHMP) recommends EU...
In the pivotal study, treatment with Gazyvaro plus bendamustine chemotherapy reduced the risk of disease worsening or death by 52 percent compared to bendamustine alone BASEL, 04-May-2016 —...
View ArticleClik here to view.
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia...
LONDON, 27-Mar-2019 — /EuropaWire/ — The LentiGlobin application for Conditional Marketing Authorization (cMAA) at the EMA from bluebird bio is still in the process of being reviewed by CHMP during...
View Article
